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Obesity is one of several factors implicated in the genesis of diabetic nephropathy (DN). Obese, hypertensive, type 2 diabetic
rats SHR/NDmcr-cp were given, for 12 weeks, either a normal, middle-carbohydrate/middle-fat diet (MC/MF group) or a high-
carbohydrate/low-fatdiet(HC/LFgroup).Dailycaloricintakewasthesameinbothgroups.Nevertheless,theHC/LFgroupgained
less weight. Despite equivalent degrees of hypertension, hyperglycemia, hyperlipidemia, hyperinsulinemia, and even a poorer
glycemic control, the HC/LF group had less severe renal histological abnormalities and a reduced intrarenal advanced glycation
andoxidativestress.Mediatorsoftherenoprotection,speciﬁcallylinkedtoobesityandbodyweightcontrol,includeareducedrenal
inﬂammation and TGF-beta expression, together with an enhanced level of adiponectin. Altogether, these data identify a speciﬁc
role of body weight control by a high-carbohydrate/low-fat diet in the progression of DN. Body weight control thus impacts on
local intrarenal advanced glycation and oxidative stress through inﬂammation and adiponectin levels.
1.Introduction
The genesis of diabetic nephropathy (DN) in type 2 diabetes
mellitus is clearly multifactorial, involving hypertension,
hyperglycemia,hyperinsulinemia,andhyperlipidemia[1–6].
Recent studies have further highlighted the role of obesity in
the renal damage observed not only in patients with obesity-
related glomerulopathy but also in overweight subjects with
type 2 diabetes [6–10].
In several previous studies, we have explored a diabetic
rat model, that is, the spontaneously hypertensive/NIH-
corpulent rat (SHR/NDmcr-cp), to unravel factors impli-
cated in DN. This rat strain has the same hypertensive
background as SHR but also a genetic mutation in the
leptin receptor gene, which leads to hyperphagia with
an attendant wide range of metabolic abnormalities, that
is, high body weight, hyperglycemia, hyperlipidemia, and
hyperinsulinemia. It develops proteinuria, and glomerular
and tubulointerstitial damages, mimicking human diabetic
nephropathy, for example, focal and segmental glomerular
sclerosis, mesangial expansion, and tubulointerstitial ﬁbrosis
[11, 12].
Previously, we demonstrated that a low caloric diet
reduced both metabolic and renal alterations independently
of blood pressure, lipid, glucose, and insulin levels. The
observation that a high-carbohydrate/low-fat diet reduces
eﬀectively body weight without calorie restriction [13, 14]
ledustouseasimilarisocaloricdietinourratmodeltobetter2 Journal of Obesity
identify factors mediating the weight-related factors involved
in the genesis of DN.
SHR/NDmcr-cp rats given a normal middle-
carbohydrate/middle-fat diet (MC/MF group) were thus
compared with similar rats fed a high-carbohydrate/low-
fat diet (HC/LF group). To our expectation, the latter
diet induced signiﬁcant less weight gain without calorie
restriction. Despite the equivalent degrees of hypertension,
hyperglycemia, hyperlipidemia, hyperinsulinemia, and
even a poorer glycemic control, the HC/LF group had
a signiﬁcantly lower proteinuria and less severe renal
histological abnormalities. The mediators of the speciﬁc
weight eﬀect on the kidney appear to be an obesity-related
inﬂammation, aggravated by a lowered anti-inﬂammatory
adiponectin level, an increased oxidative stress and advanced
glycation, and an enhanced TGF-beta expression, all of
which might constitute promising therapeutic targets.
2.MaterialsandMethods
2.1. Animals. Animal experiments were performed in accor-
dance with the guidelines of the Committee on Ethical
Animal Care and Use of Tokai University.
Male spontaneously hypertensive/NIH-corpulent rats
(SHR/NDmcr-cp) and male Wistar-Kyoto rats (WKY) were
purchased from SLC (Shizuoka, Japan). They were housed
in individual cages, in a temperature- and light-controlled
environment in an accredited animal care. SHR/NDmcr-cp
rats, aged 5 weeks, were randomly divided into two groups
and given for 12 weeks either a normal diet (CE-2, CLEA
Japan Inc., Tokyo, Japan) with tap water (MC/MF group,
10 rats), or a high carbohydrate/low fat diet (CE-2 with
tap water containing 30% sucrose) (HC/LF group, 10 rats).
Five WKY rats on a normal diet (CE-2) served as a control
group (WKY group, 5 rats). All rats were allowed unlimited
access to diet and water, and each rat’s daily dietary intake
was determined thrice weekly from the amount of actually
consumed food and ﬂuid. They were sacriﬁced at the age of
17 weeks.
2.2. Blood Pressure and Blood and Urine Biochemistry. Sys-
tolic blood pressure was determined in conscious rats by the
tail-cuﬀ method at the beginning of the study, 2wk, 4wk,
and every 4wk subsequently until euthanasia. Rats were
housed in metabolic cages for overnight collection of urine,
and blood samples were obtained at the same time intervals.
Plasma triglycerides and urinary protein concentration were
determined with an automatic analyzer (Hitachi Automatic
Clinical Analyzer 7170, Hitachi Science Systems, Ibaraki,
Japan). The following methods were used: plasma insulin
by a commercially available kit (Morinaga Biochemistry Lab,
Tokyo, Japan), HbA1c by the DCA2000 (Bayer Diagnostics,
Pittsburgh, PA), plasma adiponectin by a commercially
available ELISA kit (AdipoGen Inc., Seoul, Korea).
2.3. Semiquantitative Evaluation of Glomerulosclerosis and
Interstitial ﬁbrosis. The methods were previously described
[11, 12]. Brieﬂy, glomerulosclerosis was assessed in 4-μm
thick sections ﬁxed in methyl-Carnoy’s solution and stained
with PAS. Morphometry was performed in 50 glomeruli
selected at random in each animal. Glomerular sclerosis
was graded according to the damaged area expressed as
a percentage of total glomerular area: (0, no lesions; 1+,
1% to 25%; 2+, 25% to 50%; 3+, 50% to 75%; 4+, 75%
to 100%). Tubulointerstitial ﬁbrosis was evaluated in 4-μm
thick sections ﬁxed in 10% neutral buﬀered formaldehyde
and stained with Masson’s trichrome. Interstitial trichrome-
positive areas were counted using the capacity of software
Image-Pro Plus (Planetron, Inc., Tokyo, Japan) in ten ran-
domly obtained digital images of the renal cortex. Trichrome
positive areas on glomeruli, Bowman’s capsules or vessels
were excluded.
2.4. Semiquantitative Analysis of Macrophage Inﬁltration.
Mouse anti-rat macrophage/monocyte antibody (anti-ED-
1, Serotec, Oxford, UK) was used to stain 4-μm thick
renal sections ﬁxed in 10% neutral buﬀered formaldehyde.
ED -1-positive cells inﬁltrating the tubulointerstitium were
counted in 10 randomly selected ﬁelds in the cortex (400×
magniﬁcation).
2.5. Gene Expression Analysis. Real-time PCR was performed
by a previously described method [12] relying on One Step
RT-PCR Kit (Takara Bio Inc., Shiga, Japan), SYBR Green
I reagent (Cambrex Bio Science, Rockland, Maine), and
iCyclerPCRsystem(Bio-RadLaboratories,Hercules,CA),to
evaluatethemRNAexpressionoftransforminggrowthfactor
(TGF)-beta, connective tissue growth factor (CTGF), plas-
minogen activator inhibitor (PAI)-1, Nox2, p47phox,t u m o r
necrosis factor (TNF)-alpha, intercellular adhesion molecule
(ICAM)-1, vascular cell adhesion molecule (VCAM)-1,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Primer sequences are listed in Table 1. GAPDH mRNA
expression was used for normalization of these genes expres-
sions. Data are presented as relative values to the MC/MF
group.
2.6. Cell Culture. IRPTC was kindly provided by Dr. Julie
Ingelﬁnger. IRPTC is a cell line originating from proximal
tubular cells of male Wistar rats, immortalized by transfor-
mation with origin-defective SV 40 DNA [15]. IRPTCs were
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(Invitrogen, Carlsbad, CA), supplemented with 10% FBS.
2.7. TNF-Alpha Stimulation Assay In Vitro. IRPTCs were
cultured in 96-well plates and grown to conﬂuence. They
weresubsequentlywashedandincubatedwithserum-starved
DMEM containing 0.01, 0.1, 1ng/ml human TNF-alpha
(SIGMA-ALDRICH, Inc., St. Lois, MO) for 4 hours (n = 8).
Total RNA was isolated from IRPTCs with RNeasy mini kit
according to the manufacturer’s instructions.
2.8. Renal Pentosidine Content. The method has been previ-
ously described [11]. Brieﬂy, a 20-μL aliquot of a renal tissue
acid hydrolysate diluted by PBS was injected into a reverse-
phase HPLC system and separated on a C18 reverse-phaseJournal of Obesity 3
Table 1: Primers for real-time PCR.
Gene Forward primer (5  to 3 ) Reverse primer (5  to 3 )
TGF-beta TGCGCCTGCAGAGATTCAAG AGGTAACGCCAGGAATTGTTGCTA
CTGF CACCCGGGTTACCAATGACAA AGCCCGGTAGGTCTTCACACTG
PAI-1 GCCCAGCATTCAGCCTTTG AAGACTTTGCTGAGTGAAGGCGTAG
Nox2 CGGGACTTCGGACCCATATTC ATTCCTGTGATGCCAGCCAAC
47phox CCACGGGTATTGCTAGGATGAGA AGACTAAGGCAGCGGGTAATCAGA
TNF-alpha AACTCGAGTGACAAGCCCGTAG GTACCACCAGTTGGTTGTCTTTGA
ICAM-1 ACAAGTGCCGTGCCTTTAGCTC GATCACGAAGCCCGCAATG
VCAM-1 GGATGCCGGAGTATACGAGTGTG CAATGGCGGGTATTACCAAGGA
GAPDH GACAACTTTGGCATCGTGGA ATGCAGGGATGATGTTCTGG
column (Waters, Tokyo, Japan). Pentosidine was measured
in its eﬄuent monitored with a ﬂuorescence detector (RF-
10A; Shimadzu, Kyoto, Japan) at an excitation-emission
wavelength of 335/385nm. Synthetic pentosidine was used
as a standard.
2.9. Statistical Analysis. Data are reported as the mean
± SEM. Statistical analysis was performed with SPSS for
Windows version 15.0 (SPSS, Chicago, IL). For multiple
comparisons, one-way analysis of variance (ANOVA) and
Dunnett t test were performed. Comparisons between two
groups were performed using an unpaired t test. The
spearmancorrelationtestwasusedforcorrelativeevaluation.
P<. 05 was considered signiﬁcant.
3. Results
3.1. Body Weight. Daily caloric intake ranged from 100 to
120kcal per animal and was virtually identical in both
groups throughout the study (Figure 1(a)). Daily intake of
carbohydrate, fat, protein, and sodium was around 16.7g,
1.5g, 7.0g, and 100mg/day, respectively, in the MC/MF
group and 22.6g, 0.5g, 4.0g, and 35mg/day, respectively, in
the HC/LF group (Figures 1(b)–1(e), P<. 001).
Despite avirtuallyidenticalcaloricintake, theratsgained
less weight in the HC/LF than in the MC/MF group (P<
.01): 505 ± 21 versus 577 ± 16g at the end of the study
(Figure 2(a)).
3.2. Hypertension and Metabolic Abnormalities. Physical and
biological data of experimental rats are summarized in
Figure 2. Both groups of SHR/NDmcr-cp rats gradually
developed a similar degree of hypertension, as a consequence
oftheirSHRgeneticbackground.ComparedtocontrolWKY
rats, both the MC/MF and the HC/LF groups suﬀered a wide
range of hyperphagia induced metabolic abnormalities, that
is, high body weight, hyperglycemia (as evidenced by HbA1c
levels), hyperinsulinemia, and hypertriglyceridemia.
Compared with the MC/MF group, the HC/LF group
gained signiﬁcantly less weight (P<. 01), and had a
signiﬁcantly worse HbA1c level (P<. 001). Other metabolic
abnormalities, that is, hypertriglyceridemia and hyperinsu-
linemia, were equivalent between the two groups.
3.3. Renal Involvement. The progressive rise in proteinuria
observed in the MC/MF group was markedly attenuated in
theHC/LFgroupthroughoutthestudy(Figure 3).Attheend
of the study, proteinuria reached 59.8 ± 7.2mg/day in the
MC/MF group versus 19.6 ± 2.2mg/day in the HC/LF group
(P<. 001), values to be compared to 9.8 ± 0.6mg/day in the
WKY rats (P<. 001).
Representative periodic acid-Schiﬀ- (PAS-) or Masson’s
trichrome-(MT-) stained renal pictures obtained at the end
of the study in each animal group are shown in Figure 4.
Glomerular sclerosis (Figures 4(a)–4(c)) and tubulointersti-
tial ﬁbrosis (Figures 4(d)–4(f)) were visible in both groups
but less in the HC/LF group than in the MC/MF group.
On semiquantitative analysis (Table 2), glomerulosclero-
sis and interstitial ﬁbrosis were signiﬁcantly more severe in
both experimental groups than in the WKY group (P<. 001
and P<. 05, resp.) but were milder in the HC/LF group than
in the MC/MF group (P<. 001 and P<. 05, resp.).
3.4. Molecular Biochemical Analyses. Obesity-related cyto-
kines (e.g., adiponectin and TNF-alpha) levels, inﬂam-
mation, transforming growth factor (TGF)-beta, oxidative
stress, and advanced glycation were assessed to ascertain the
biological mechanisms involved in the better renal outcome
in the HC/LF group.
3.5. Inﬂammation and Obesity-Related Cytokines. Inﬂamma-
tion has been associated with obesity [16]. Macrophage
inﬁltration was milder in the HC/LF than in the MC/MF
group (Figures 4(g) and 4(h)). On semiquantitative analysis,
tubulointerstitial inﬁltration was signiﬁcantly (P<. 05)
milder in the HC/LF group than in the MC/MF group
(Figure 5(a)).
TNF-alpha mRNA expression in kidney tissues was
signiﬁcantly (P<. 05) lower in the HC/LF than in the
MC/LF group with a parallel decrease in the expression of
intercellular adhesion molecule (ICAM)-1 and vascular cell
adhesion molecule (VCAM)-1 (Figure 5(b)).
Adiponectin is an anti-inﬂammatory cytokine secreted
by adipocytes [17, 18]. Its plasma level was signiﬁcantly
(P<. 01) higher in the HC/LF than in the MC/MF group
(Figure 5(c)). Interestingly, plasma adiponectin level, deter-
mined in all SHR/NDmcr-cp rats, was inversely correlated4 Journal of Obesity
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Figure 1: Daily diet intake. (a) Daily calorie intake, (b) carbohydrate intake, (c) fat intake, (d) protein intake, and (e) sodium intake in
MC/MF (closed square) and HC/LF (open square). ∗∗P<. 01, ∗∗∗P<. 001 versus MC/MF.
with body weight (r = 0.602, P<. 01) and with proteinuria (r
= 0.654, P<. 01). Of note, body weight was also signiﬁcantly
correlatedwithproteinuriainallexperimentalrats(P<. 001,
r = 0.708).
3.6. TGF-Beta. TGF-beta has been implicated in the devel-
opment of diabetic renal injury [19, 20]. TGF-beta mRNA
expression in kidney tissue was signiﬁcantly (P<. 01) lower
in the HC/LF than in the MC/MF group, with a parallelJournal of Obesity 5
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Figure 2: Metabolic abnormalities. (a) Body weight, (b) HbA1c, (c) triglycerides, (d) insulin, and (d) systolic blood pressure. WKY (closed
triangle), MC/MF (closed square), and HC/LF (open square). ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus WKY; ††P<. 01,†††P<. 001 versus
MC/MF.6 Journal of Obesity
Table 2: Morphologic evaluation of glomerular sclerosis and tubulointerstitial ﬁbrosis at the end of study.
WKY MC/MF HC/LF
Glomerular sclerosis score 0.13 ± 0.02 0.63 ± 0.03∗∗∗ 0.43 ± 0.02∗∗∗†††
Tubulointerstitial ﬁbrosis (%) 1.8 ± 0.14 .6 ± 0.3∗∗∗ 3.3 ± 0.4∗†
∗P<. 05, ∗∗∗P<. 001 versus WKY; †P<. 05, †††P<. 001 versus MC/MF.
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Figure 3: Changes of proteinuria. WKY (closed triangle), MC/MF
(closed square), and HC/LF (open square). ∗∗P<. 01, ∗∗∗P<. 001
versus WKY; †††P<. 001 versus MC/MF.
decrease in the expression of TGF-beta-related genes, that
is, connective tissue growth factor (CTGF) and plasminogen
activator inhibitor (PAI)-1 (Figure 6(a)).
The interrelation between TGF-beta and TNF-alpha
expression was further tested in vitro in cultured rat
proximal tubular cells (IRPTC) [15]. Incubation for 4
hours in a TNF-alpha fortiﬁed medium signiﬁcantly (P<
.05) increased mRNA expression of TGF-beta in a dose-
dependent manner (Figure 6(b)). These data conﬁrm previ-
ous conclusions [21, 22].
3.7. Advanced Glycation. Advanced glycation and its protein
modiﬁcations, that is, advanced glycation end products
(AGEs), have been implicated in diabetic renal injury [23–
25]. At the end of the study, renal pentosidine content, a
surrogate marker of advanced glycation, was markedly (P<
.01) lower in the LC/HF group than in the MC/MF group
(Figure 7(a)).
3.8. Oxidative Stress. Oxidative stress, a mediator of diabetic
renal injury, implicates NADPH oxidase, one of the major
sources of cellular reactive oxygen species (ROS) [26]. The
mRNAexpressionsoftwosubunitsofNADPHoxidase,Nox2
and p47phox, measured in renal tissues, were signiﬁcantly
(P<. 05, P<. 01, resp.) lower in the HC/LF than in the
MC/MF group (Figure 7(b)).
In all diabetic rats, renal Nox2 and 47phox mRNAs
expression levels were signiﬁcantly correlated with TNF-
alpha (r = 0.450, P<. 05; r = 0.727, P<. 001, resp.),
with TGF-beta (r = 0.764, P<. 001; r = 0.699, P<. 01,
respectively), and with renal pentosidine content (r = 0.719,
P<. 001; r = 0.565, P<. 01, resp.).
4. Discussion
Thepresentstudyhighlightsbodyweightcontrolasamarked
contributor to the slowing of the progression of DN. It
identiﬁes inﬂammation, oxidative stress, advanced glycation,
TGF-beta, and adiponectin as possible mediators of this
eﬀect.
Use of the same rat model in our several previous
studies [11, 12, 27–29] has provided a detailed picture
of the features involved in the renal disorder observed in
SHR/NDmcr-cpgivenanadlibitumaccesstoastandarddiet.
In the present study, the control group of rats on a middle-
carbohydrate/middle-fat diet exhibits the same spectrum
of abnormalities, that is, high body weight, hypertension,
hyperglycemia with hyperinsulinemia, elevated lipids and
TGF-beta expression together with proteinuria, glomerular
and interstitial ﬁbrosis with evidence of intrarenal advanced
glycation and oxidative stress. Unraveling the sequence of
events leading to DN in this model is of importance as it
might oﬀer a clue to a better prevention and treatment of the
renal disease complicating the outcome of diabetic patients.
The present data demonstrate that body weight control
by a high-carbohydrate/low-fat diet plays a role in the
slowing of the development of DN, independently of calorie
intake. In agreement with our ﬁndings, in human, a high-
carbohydrate/low-fat diet reduces eﬀectively body weight
without calorie restriction [13, 14]. The mechanism for
body weight control by a high-carbohydrate/low-fat diet still
remains unknown. Its mitigation in the HC/LF group leads
lower proteinuria and less severe renal lesions, despite an
equivalent caloric intake and similar degrees of hyperten-
sion, hyperlipidemia, hyperinsulinemia, and an even poorer
glycemic control. In a previous study, a similar eﬀect of body
weight control, achieved by a lower caloric intake in the
same rat model, provided the same renoprotection, again
independently of blood pressure, glucose, insulin and lipid
levels [28]. The beneﬁts of body weight control appear thus
independent of the latter factors as well as of caloric intake.
Ofimportance,renoprotectionwasachievedinbothiso-and
hypocaloric rat models together with a parallel reduction of
intrarenal advanced glycation and oxidative stress, both of
which clearly play a critical role in the development of DN.
The mediation of obesity’s eﬀects on DN remains to be
identiﬁed. TGF-beta and its regulated products, CTGF and
P A I - 1 ,m i g h tb es u c ha g e n t sa st h e yh a v eb e e np r e v i o u s l y
implicated in DN [19, 20, 30–32]. In the same rat strain,
we have previously adduced evidence that insulin raisesJournal of Obesity 7
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Figure 4: Glomerular sclerosis, tubulointerstitial ﬁbrosis, and macrophage inﬁltration. PAS-stained (a)–(c), Masson trichrome-stained (d)–
(f), or ED-1-immunostained (g) and (h) renal tissues. WKY rats (a), (d), MC/MF (c), (f), (h), and HC/LF (b), (e), (g) at the end of study.
Arrows indicate ED-1 positive cells. Original magniﬁcation 400× ((a)–(c), (g), (h)) and 200× (d)–(f).
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Figure 5: Inﬂammation in renal tissues. (a) ED-1 positive cells in tubulointerstitial area, (b) gene expressions of TNF-alpha, ICAM-1, and
VCAM-1, and (c) plasma adiponectin level in MC/MF (white bar) and HC/LF (black bar). ∗P<. 05, ∗∗P<. 01.8 Journal of Obesity
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Figure 6: TGF-beta in renal tissues and its induction in vitro by TNF-alpha. (a) Gene expressions of TGF-beta, CTGF, and PAI-1 in MC/MF
(white bar) and HC/LF (black bar).∗P<. 05, ∗∗P<. 01. (b) Eﬀects of TNF-alpha on TGF-beta mRNA expressions in vitro in cultured rat
proximal tubular cells (IRPTC). ∗P<. 05, ∗∗P<. 01.
TGF-beta expression and that this rise was associated with
renal damage [12]. We now show that the lower body weight
induced in the HC/LF group reduces TGF-beta expression,
and attendant CTGF and PAI-1 expressions. Interestingly,
TGF-beta expression fell despite unchanged insulin levels,
suggesting that body weight control modiﬁed its expression
independently of glucose and insulin levels.
Obesity triggers an inﬂammatory reaction which has
been incriminated in the development of DN [16, 33–
35]. Our data support this hypothesis. The kidneys of the
M C / M Fg r o u pr e p o r t e di nt h i sa sw e l la si np r e v i o u ss t u d i e s
[28] are inﬁltrated by macrophages. The lower body weight
HC/LF rats are characterized by a decreased renal inﬁltration
by macrophages and a parallel reduction in the mRNA
expression of TNF-alpha and its related proteins, ICAM-
1 and VCAM-1. Interestingly, we demonstrate, in cultured
rat proximal tubular cells, that TNF-alpha and TGF-beta
are interrelated: TNF-alpha per se upregulates TGF-beta
mRNA, a previously reported observation [21, 22]. The
correlation observed between both cytokine levels conﬁrms
this conclusion.
Adiponectin is an anti-inﬂammatory, anti-atherogenic,
and anti-oxidative peptide downregulated in obese patients
[18]. Its plasma level correlates inversely with proteinuria
in diabetes [36, 37], a ﬁnding corroborated by the present
study. Plasma adiponectin levels were higher in the HC/LF
group which exhibited slower progression of DN, suggesting
that body weight control augmented the adiponectin plasma
level, its anti-inﬂammatory eﬀect, and thus renoprotection.
This hypothesis is supported by Ohashi et al.’s observation in
adiponectin knockout mice with subtotal nephrectomy [38]:
adiponectin deﬁciency exacerbated albuminuria and renal
lesions together with an increased inﬂammation, TGF-beta
levels, and oxidative stress.
The beneﬁts of adiponectin in the prevention of DN
are of major interest. We previously demonstrated in
the same diabetic rat strain that pioglitazone, a class of
thiazolidinediones (TZDs), protected the diabetic kidney
by improving hyperinsulinemia and TGF-beta expression
[12]. In this context, it is of note that TZDs upregulate
plasma adiponectin level, raising the possibility of TZDs’
renoprotection might be attributed, at least in part, to the
speciﬁc induction of adiponectin [17, 37].
Both advanced glycation and oxidative stress are clearly
implicated in DN [23–26]. Indeed several AGE inhibitors,
forexample,pyridoxamine,ALT-711,andLR-90,preventthe
development of diabetic nephropathy [39–42], suggesting
that accumulation of AGEs is an important risk factor
for diabetic renal injury. Angiotensin II receptor blockers
(ARBs) are also known to protect the diabetic kidney, at least
in part, via inhibition of advanced glycation and oxidative
stress, independently of body weight [11, 29]. The lowered
renal pentosidine content observed in the HC/LF group
conﬁrms this contention. It is of special interest as it occurs
despite higher plasma glucose levels than in the MC/MF
control group and might thus reﬂect a lower oxidative
stress. Advanced glycation and oxidative stress are indeed
interrelated. Under diabetic conditions, AGEs, TGF-beta,
and proinﬂammatory cytokines generate reactive oxygen
species (ROS) via NADPH oxidase which, in turn, ampliﬁesJournal of Obesity 9
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Figure 7: Advanced glycation and oxidative stress in renal tissues. (a) Renal pentosidine content, and (b) gene expressions of Nox2 and
p47phox in MC/MF (white bar) and HC/LF (black bar).∗P<. 05, ∗∗P<. 01.
AGEs formation, TGF-beta expression, and inﬂammation
[26, 43–45]. In the HC/LF group, both advanced glycation,
assessed by the renal pentosidine content, and oxidative
stress, evaluated by the renal mRNA expressions of two
subunits of NADPH oxidase, Nox2 and p47phox, decreased
signiﬁcantly. In our model, in vivo changes in local oxidative
stress and advanced glycation might eventually mediate the
obesity-related eﬀect on the diabetic kidney.
We cannot rule out that the underlying hypertension,
diabetes, and obesity are not playing a role in this model.
Furthermore, the intake of fat is implicated in the progres-
sion of renal damage via lipid accumulation, inﬂammation,
and renal hemodynamics change [46, 47]. The beneﬁcial
changes observed in the HC/LF group could be attributed
to the low fat content of diet, more than to changes in
body weight. The sodium intake was also less in the HC/LF
group. The local glomerular hemodynamics change might
therefore occur, independently of systemic blood pressure
[48]. Admittedly, the protein contents in diet also diﬀer in
our two experimental rat groups. Although this possibility
cannot be formally ruled out, it appears unlikely as previous
studiesbyothershaveshowninSHRratsthatdietaryprotein
content did not aﬀect the development of proteinuria and
renal lesions [49].
In conclusion, body weight control by a high-
carbohydrate/low-fat diet slows the progression of diabetic
nephropathy through the suppression of inﬂammation,
sclerotic change, and oxidative stress. They identify adi-
ponectin, TNF-alpha, TGF-beta, and AGEs as potential ther-
apeutic targets for the prevention of the renal consequences
of type 2 diabetes.
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